PCSK9 and familial hyperaldosteronism: This open-label, observational study focused on the effect of PCSK9 inhibitors (PCSK9-i) on plasma lipoprotein functions, i.e., HDL-CEC and serum cholesterol loading capacity (CLC) in FH subjects.